For research use only. Not for therapeutic Use.
ILK-IN-3（Cat No.:I015045）, is a chemical compound of interest in the field of pharmacology and molecular biology. It is a selective inhibitor designed to target integrin-linked kinase (ILK), an enzyme involved in various cellular signaling pathways. By inhibiting ILK, ILK-IN-3 has the potential to influence cellular processes such as cell adhesion, migration, and proliferation. This compound is commonly used in laboratory research to investigate the role of ILK in different biological contexts and may hold promise for the development of targeted therapies for diseases and conditions where ILK dysregulation plays a significant role, such as cancer and fibrosis.
| Catalog Number | I015045 |
| CAS Number | 6975-75-3 |
| Molecular Formula | C₁₀H₁₂N₆O |
| Purity | ≥95% |
| Target | Protein Tyrosine Kinase/RTK |
| Storage | -20°C |
| IUPAC Name | 4-[(4-methoxyphenyl)diazenyl]-1H-pyrazole-3,5-diamine |
| InChI | InChI=1S/C10H12N6O/c1-17-7-4-2-6(3-5-7)13-14-8-9(11)15-16-10(8)12/h2-5H,1H3,(H5,11,12,15,16) |
| InChIKey | QNRNTYHAOBVOKW-UHFFFAOYSA-N |
| SMILES | COC1=CC=C(C=C1)N=NC2=C(NN=C2N)N |
| Reference | [1]. Jessica Kalra, et al. Validating the Use of a Luciferase Labeled Breast Cancer Cell Line, MDA435LCC6, as a Means to Monitor Tumor Progression and to Assess the Therapeutic Activity of an Established Anticancer Drug, Docetaxel (Dt) Alone or in Combination With the ILK Inhibitor, QLT0267. Cancer Biol Ther. 2011 May 1;11(9):826-38. |
